Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics
about
Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)A novel three-dimensional stromal-based model for in vitro chemotherapy sensitivity testing of leukemia cells.
P2860
Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Dose study of the multikinase ...... kinetics, and pharmacodynamics
@ast
Dose study of the multikinase ...... kinetics, and pharmacodynamics
@en
type
label
Dose study of the multikinase ...... kinetics, and pharmacodynamics
@ast
Dose study of the multikinase ...... kinetics, and pharmacodynamics
@en
prefLabel
Dose study of the multikinase ...... kinetics, and pharmacodynamics
@ast
Dose study of the multikinase ...... kinetics, and pharmacodynamics
@en
P2093
P2860
P356
P1476
Dose study of the multikinase ...... kinetics, and pharmacodynamics
@en
P2093
Dirk Van Bockstaele
Gemma Dickinson
Georg Dorfner
Jacqueline K Akunda
Michael Lahn
Renata Meyer
Richard F Schlenk
Sada Pillay
Susanne Herndlhofer
Thorsten Füreder
P2860
P304
P356
10.2147/CMR.S19341
P407
P577
2011-05-10T00:00:00Z